Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ($1.16 billion), adding an antibody-based therapy for acute myeloid ...
Measuring trust isn’t enough. Furthering knowledge about the institutions and norms of science is the best way to build credibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results